drug affinity complex is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Climate change is predicted to have significant effects on global potato production. Like many crops, potatoes are likely to be affected by changes in atmospheric carbon dioxide, temperature and precipitation, as well as interactions between these factors. As well as affecting potatoes directly, climate change will also affect the distributions and populations of many potato diseases and pests. While the potato is less important than maize, rice, wheat and soybeans, which are collectively responsible for around two-thirds of all calories consumed by humans (both directly and indirectly as animal feed), it still is one of the world's most important food crops. Altogether, one 2003 estimate suggests that future (2040–2069) worldwide potato yield would be 18–32% lower than it was at the time, driven by declines in hotter areas like Sub-Saharan Africa, unless farmers and potato cultivars can adapt to the new environment. Potato plants and crop yields are predicted to benefit from the CO2 fertilization effect, which would increase photosynthetic rates and therefore growth, reduce water consumption through lower transpiration from stomata and increase starch content in the edible tubers. However, potatoes are more sensitive to soil water deficits than some other staple crops like wheat. In the UK, the amount of arable land suitable for rainfed potato production is predicted to decrease by at least 75%. These changes are likely to lead to increased demand for irrigation water, particularly during the potato growing season. Potatoes grow best under temperate conditions.
Brenner has developed targeted, quantitative analysis of the NAD+ metabolome and made fundamental contributions to NAD metabolism including discovery of nicotinic acid riboside-dependent NAD synthesis, elucidating the mechanism of synthesis of nicotinic acid adenine dinucleotide phosphate, and discovering multiple conditions in which NAD metabolism is dysregulated in disease. Brenner is active in translating NR technologies to treat and prevent human conditions that disturb the NAD system including cancer diabetic and chemotherapeutic peripheral neuropathy, heart failure, central brain injury, inflammation, mitochondrial myopathy pellagra, and infections such as coronavirus infection Brenner's work included the first human trial of NR in 2016, which demonstrated safe oral availability as an NAD+ precursor, thereby creating the foundational intellectual property for the NAD boosting industry. Though Brenner was the first to show that NR increases SIR2 activity, improves gene silencing, and can extend yeast lifespan, his work has not emphasized sirtuins or nonspecific anti-aging claims and instead emphasizes how NR repairs inflammatory conditions and metabolic stresses that dysregulate NAD+ and NADPH.
The Laténium is an archeology museum located in Laténa, Switzerland. Its name refers to the famous nearby site of La Tène which gave its name to the Second European Iron age. The Laténium is composed of a 2,500 m2 (27,000 ft2) park and a museum building which also harbours the archaeological section of the Heritage Offices of the State of Neuchâtel, as well as the chair of prehistory of the University of Neuchâtel. The museum and its park are built on what used to be three archaeological sites that were excavated during the construction of the A5 motorway. Theses sites date from the Upper Paleolithic, Bronze Age and Neolithic. The park features dolmens and glacial erratics, reconstitutions of prehistoric and antique devices (a La Tène house, a Gallo-Roman ship and a Celtic bridge, notably), and modern works of art. The museum displays the Bevaix boat, a 20 m (66 ft) Gallo-Roman ship found in Bevaix. Items from periods comprised between the Paleolithic to the Middle Ages are on display, including the remains of a Magdalenian hunting camp.
Sources: en.wikipedia.org
For each diprotic acid titration curve, from left to right, there are two midpoints, two equivalence points, and two buffer regions. Due to the successive dissociation processes, there are two equivalence points in the titration curve of a diprotic acid. The first equivalence point occurs when all first protons from the first ionization are titrated. In other words, the amount of OH− added equals the original amount of H2A at the first equivalence point. The second equivalence point occurs when all protons are titrated. Therefore, the amount of OH− added equals twice the amount of H2A at this time. For a weak diprotic acid titrated by a strong base, the second equivalence point must occur at pH above 7 due to the hydrolysis of the resulted salts in the solution. At either equivalence point, adding a drop of base will cause the steepest rise of the pH value in the system.
== Design precautions == If sufficient reactivity control authority is available, the reactor can be restarted, but a xenon burn-out transient must be carefully managed. As the control rods are extracted and criticality is reached, neutron flux increases many orders of magnitude and the 135Xe begins to absorb neutrons and be transmuted to 136Xe. The reactor burns off the nuclear poison. As this happens, the reactivity increases and the control rods must be gradually re-inserted or reactor power will increase. The time constant for this burn-off transient depends on the reactor design, power level history of the reactor for the past several days (therefore the 135Xe and 135I concentrations present), and the new power setting. For a typical step up from 50% power to 100% power, 135Xe concentration falls for about 3 hours. The first time 135Xe poisoning of a nuclear reactor occurred was on September 28, 1944, in Pile 100-B at the Hanford Site. The B Reactor was a plutonium production reactor built by DuPont as part of the Manhattan Project. The reactor was started on September 27, 1944, but the power dropped unexpectedly shortly after, leading to a complete shutdown on the evening of September 28. Next morning the reaction restarted by itself. The physicists John Archibald Wheeler, working for DuPont at the time, and Enrico Fermi were able to identify that the drop in the neutron flux and the consequent shutdown was caused by the accumulation of 135Xe in the reactor fuel.
Israel is widely believed to possess nuclear weapons, with an estimated stockpile of between 90 and 400 nuclear warheads. Israel is the only nuclear-armed country that does not officially acknowledge its nuclear weapons capability. Some scholars have argued that Israel's nuclear weapons have incentivized Iran to develop its own nuclear program, seen as maintaining a balance of nuclear deterrence, or causing a regional nuclear arms race. Citing security threats, Israel rejects international calls to accede to the Treaty on the Non-Proliferation of Nuclear Weapons or to participate in negotiations of a Middle East nuclear weapon free zone. This has frustrated both US and UK diplomatic efforts towards such a zone. Scholars also suggest US tacit acceptance of the Israeli nuclear weapons capability is seen as a double standard that undermines its diplomatic credibility in Middle East nonproliferation negotiations.
Sources: en.wikipedia.org
Mulliken (1896–1986), American physicist and chemist known for molecular orbital theory, 1966 Nobel Prize in Chemistry Jnanendra Nath Mukherjee(1893-1983), Indian chemist known for work on the electrochemistry of colloids Kary Mullis (1944–2019), American biochemist who invented the polymerase chain reaction, 1993 Nobel Prize in Chemistry Earl Muetterties (1927–1984), American chemist known for work on boranes and various aspects of catalysis Catherine J. Murphy (born 1964), American chemist and materials scientist known for work on nanomaterials
== Author == Fascia: The Tensional Network of the Human Body: The science and clinical applications in manual and movement therapy. Elsevier Health Sciences. 26 February 2013. ISBN 978-0-7020-5228-6. Fascia in Sport and Movement. Handspring. 2015. ISBN 978-1-909141-07-0. Fascial Fitness: How to be Vital, Elastic and Dynamic in Everyday Life and Sport. Lotus. 2017. ISBN 978-1-905367-71-9. Fascia: The Tensional Network of the Human Body Expert Consult: Fascia: The Tensional Network of the Human Body - E-Book. Elsevier Health Sciences. 8 December 2021. ISBN 978-0-7020-8413-3. Fascial Fitness, Second Edition: Practical Exercises to Stay Flexible, Active and Pain Free in Just 20 Minutes a Week. North Atlantic Books. 6 July 2021. ISBN 978-1-62317-675-4. Fascia in Sport and Movement, Second edition. Jessica Kingsley Publishers. 30 March 2021. ISBN 978-1-912085-78-1. Der Faszien-Code: Wie die Genetik des Bindegewebes deine Gesundheit beeinflusst und du typgerecht trainierst, um Beweglichkeit und Fitness zu optimieren. Riva Verlag. 18 February 2024. ISBN 978-3-7453-2298-9.
2.) Isoenzymes of creatine phosphokinase: Creatine kinase (CK) or creatine phosphokinase (CPK) catalyses the interconversion of phospho creatine to creatine . CPK exists in 3 isoenzymes. Each isoenzymes is a dimer of 2 subunits M (muscle), B (brain) or both
As of 2019, there were an estimated 72,000 centenarians living in the U.S.; the 2020 census officially counted 80,139, and the 2010 census had 53,364. However, the U.S. Census Bureau claimed in 1999 that as many as a third of people stating their age as over 100 might be exaggerating. In the United States, centenarians may request a letter of congratulation from the president of the United States to mark their longevity. Strom Thurmond became the first sitting Senator to reach 100 on 5 December 2002. Jimmy Carter became the first former president to reach the age of 100 on 1 October 2024. Today also presents a segment honoring centenarians and older, sponsored by Smuckers. The tradition was created in 1983 by weather presenter Willard Scott, and is now presented by his successor Al Roker. In the state of New Mexico, centenarians have been exempt from state income tax since tax year 2002, if they are not dependents of another taxpayer.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.